Saturday, October 31, 2026

Tesla Stock Rises So Far On Friday, Outperforms Market

ViaNews Editorial Team

November 27, 2020

Tesla Stock Rises So Far On Friday, Outperforms Market

Tesla has been somewhat immune to the crisis with its shares jumping 3.86% to $596.16 at 11:05 EST on Friday, after three consecutive sessions in a row of gains. The Nasdaq Stock Market is rising 1.07% to $12,224.10, after three consecutive sessions in a row of gains, on what as yet seems, an all-around positive trend exchanging session today.

Tesla's last close was $574.00, 0.29% below its 52-week high of $597.89.

Tesla's sales growth is 35.3% for the ongoing quarter and 60% for the next. The company's growth estimates for the current quarter and the next is 112.2% and 265.2%, respectively.

Year-on-year quarterly revenue growth grew by 39.2%, now sitting on 28.18B for the twelve trailing months.

Tesla's stock is valued at $596.16 at 11:05 EST, below its 52-week high of $597.89 and way higher than its 52-week low of $65.45.

Tesla's value is way above its 50-day moving average of $440.84 and way higher than its 200-day moving average of $333.87.

Tesla-heavy etfs ride along as company gets a price upgrade. According to MarketWatch on Mon Nov 23, "Exchovere-traded funds with heavy exposure to Tesla Inc."

According to Bloomberg Quint on Tue Nov 24, "Musk Hints Again at Longer-Range Teslas and Hatchback for Europe."

According to Bloomberg Quint on Tue Nov 24, "Tesla Nears Half a Trillion Mark After Soaring 525% This Year."

According to Bloomberg Quint on Wed Nov 25, "Nikola, Tesla Shares Fall as EV Rally Frenzy Comes to a Halt."

According to MarketWatch on Wed Nov 25, "Tesla issues recall of 9,000-plus Model X and Model Y vehicles."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com